IPVC 2021 Committees

IPVC 2021 Committees

IPVC 2021 Executive Committee

IPVC 2021 Co-Chairs

Margaret Stanley
United Kingdom

Margaret Stanley is Emeritus Professor of Epithelial Biology in the University of Cambridge
and Honorary Fellow of Christs College, Cambridge. She has a lifetime award
for contribution to research on cervical cancer and cervical precancers from the American
Society for Colposcopy and Cytopathology (ASCCP) and a lifetime award for achievement
from the IPVS.

Margaret Stanley
United Kingdom
Ann Burchell
Canada

Dr. Ann Burchell is Research Director at the Department of Family and Community Medicine and Scientist at the MAP Centre for Urban Health Solutions at St. Michael’s Hospital, Toronto. She is a Canada Research Chair in Sexually Transmitted Infection Prevention. She holds degrees in epidemiology from the University of Toronto (MSc) and McGill University (PhD) and has academic appointments as Associate Professor, Department of Family and Community Medicine, Faculty of Medicine, and Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto; Adjunct Professor, Division of Cancer Epidemiology, McGill University; and Adjunct Scientist, Institute for Clinical Evaluative Medicine, Toronto.

Dr. Burchell’s research program focuses on the epidemiology of human immunodeficiency virus (HIV) infection, human papillomavirus (HPV), syphilis, and other sexually transmitted infections (STIs). Its goal is to generate evidence for effective and practical strategies to prevent STIs and STI-related cancers in high-risk populations, including people living with or at risk for HIV.

She has extensive methodological experience in the design and implementation of: observational longitudinal studies with primary and secondary data; sexual behaviour and health-access questionnaires; natural history studies using laboratory markers of infection; and pragmatic randomized trials for HPV prevention and improved screening for syphilis, cervical and anal cancer. She currently holds a Foundation Grant from the Canadian Institutes of Health Research.

Ann Burchell
Canada

IPVC 2021 Local Organizing Committee

Ann Burchell
Canada

Dr. Ann Burchell is Research Director at the Department of Family and Community Medicine and Scientist at the MAP Centre for Urban Health Solutions at St. Michael’s Hospital, Toronto. She is a Canada Research Chair in Sexually Transmitted Infection Prevention. She holds degrees in epidemiology from the University of Toronto (MSc) and McGill University (PhD) and has academic appointments as Associate Professor, Department of Family and Community Medicine, Faculty of Medicine, and Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto; Adjunct Professor, Division of Cancer Epidemiology, McGill University; and Adjunct Scientist, Institute for Clinical Evaluative Medicine, Toronto.

Dr. Burchell’s research program focuses on the epidemiology of human immunodeficiency virus (HIV) infection, human papillomavirus (HPV), syphilis, and other sexually transmitted infections (STIs). Its goal is to generate evidence for effective and practical strategies to prevent STIs and STI-related cancers in high-risk populations, including people living with or at risk for HIV.

She has extensive methodological experience in the design and implementation of: observational longitudinal studies with primary and secondary data; sexual behaviour and health-access questionnaires; natural history studies using laboratory markers of infection; and pragmatic randomized trials for HPV prevention and improved screening for syphilis, cervical and anal cancer. She currently holds a Foundation Grant from the Canadian Institutes of Health Research.

Ann Burchell
Canada
Gina Ogilvie
Canada

Gina Ogilvie, MD MSc FCFP DrPH is a Tier 1 Canada Research Chair in Global Control of HPV related diseases and prevention, and Professor at the University of British Columbia in the School of Population and Public Health. She is also Senior Public Health Scientist and Public Health Physician at BC Centre for Disease Control; Senior Research Advisor at the BC Women’s Hospital and Health Centre. She was previously Medical Director of Clinical Prevention Services at BC Centre for Disease Control where she provided both operational and scientific leadership to an integrated public health unit with over 100 staff. This unit focuses on providing public health leadership and service in STIs, HIV, Hepatitis and Tuberculosis provincially, nationally and globally. Dr. Ogilvie is currently principal investigator on over 10 million dollars in research grants and she has received funding from NIH, PHAC, CIHR, Michael Smith Foundation for Health Research, Canadian Foundation for Innovation and private foundations including BC Women’s Hospital Foundation among others. Her research is focused on both the public health and clinical aspects of reproductive health, sexually transmitted infections, HPV screening and the HPV vaccine, and her findings have been highly influential in setting and directing health policy both in Canada and globally. Among other research projects, she is principal investigator for the ASPIRE program, a global health initiative conducting research and providing women-centred, innovative solutions for cervical cancer prevention and reproductive health in sub-Saharan Africa. She also leads HPV FOCAL, which is a randomized trial of over 25,000 women comparing primary screening for cervical cancer, and QUEST, a pragmatic randomized trial defining the effectiveness of reduced dosing of the HPV vaccine.
She has published over 175 peer reviewed manuscripts and provides advice and consultation to national and global institutions, including the Canadian Partnership Against Cancer, Public Health Agency of Canada, the World Health Organization and Pan American Health Organization and Ministries of Health globally on STI, HIV and HPV vaccine policy and programming. She speaks widely at international and national research and education conferences, and has supervised medical students, residents, and graduate students throughout her career. Dr. Ogilvie received her MD from McMaster University, and completed a specialty in Family Medicine and a fellowship in Population Health and Primary care. She received her Master of Science at UBC, and her Doctorate in Public Health from the University of North Carolina Gillings School of Global Public Health. Dr. Ogilvie is the recipient of many prestigious honours, including The American Sexually Transmitted Diseases Association Achievement Award (2020); IUSTI Inaugural Lecture (2020), Michael S. O’Malley Alumni Award for Publication Excellence (2019); YWCA Woman of Distinction (2018); President’s Award, Children and women’s Health Centre of BC (2018); Options for Sexual health Sexual Health Champion of the Year (2018); Provincial Health Officer’s Award for Excellence in Public health (2015); Researcher of the Year, College of Family Physicians of Canada (2014); YWCA Women of Distinction Nominee (2014); Distinguished Achievement in Research, Faculty of Medicine, University of British Columbia (2014). In 2019, she was part of the Governor General’s Official Delegation to the 25th Commemoration of the Rwandan Genocide. She is one of the inaugural recipients of the highly prestigious CIHR ‘Foundation Grant’ awards, given to leading scholars to pursue 7 years of research in a field.

Gina Ogilvie
Canada
Aisha Lofters
Canada

Aisha is a scientist at the Women's College Research Institute (WCRI), adjunct scientist at IC/ES, and an Associate Professor in the Department of Family and Community Medicine at the University of Toronto. She currently holds a New Investigator Award from the Canadian Institutes of Health Research, and holds the Chair in Implementation Science at the Peter Gilgan Centre for Women’s Cancers at Women’s College Hospital in partnership with the Canadian Cancer Society.

Aisha is also the Provincial Primary Care Lead, Cancer Screening at Cancer Care Ontario (Ontario Health). Her research program focusses on improving quality of care in cancer screening and prevention, particularly for populations that experience marginalization.

Aisha Lofters
Canada
Troy Grennan
Canada

Dr. Troy Grennan is an infectious diseases physician and researcher in Vancouver, Canada. He is currently the Physician Lead for the Provincial HIV/STI Program at the BC Centre for Disease Control, as well as a Clinical Associate Professor in the Division of Infectious Diseases at the University of British Columbia. Following specialty training in infectious diseases and medical microbiology, he completed a CIHR Canadian HIV Trials Network postdoctoral fellowship examining human papillomavirus (HPV)-associated anal cancer screening in HIV-positive men who have sex with men (MSM). He is currently Co-Principal Investigator on the CIHR Team Grant “HPV Screening and Vaccine Evaluation in HIV-Positive MSM” and the recently funded, “Predicting and Evaluating Anal Cancer in HIV (PEACH) using novel biomarkers”, as well as a number of other projects examining anal cancer screening and HPV vaccination in MSM. His other research and clinical work focuses on HIV and STI prevention with a focus on MSM, and he is Principal Investigator on the DISCO (Doxycycline as an Intervention for STI ChemOprophylaxis) study, a multicentre RCT examining the use of doxycycline for bacterial STI prevention.

Troy Grennan
Canada
Joel Palefsky
USA

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine. Dr. Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day. He is the founder and director of the world’s first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center. He is the chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium. He is the immediate past president of the International Papillomavirus Society and is the founder and immediate past president of the International Anal Neoplasia Society. He is a member of the ASCI and AAP. His research interests include the molecular pathogenesis and natural history of HPV-related disease, including in the setting of HIV infection, HPV prophylactic and therapeutic vaccines, secondary prevention of anal cancer, and treatment of HPV-related disease.

Joel Palefsky
USA
Eduardo Franco
Canada

He is trained in public health microbiology at University of North Carolina and at the Centers for Disease Control, and as a cancer epidemiologist at the National Institutes of Health, International Agency for Research on Cancer, and Louisiana State University. Since 1985, his research has focused on epidemiology and prevention of gynecologic, anogenital, oral, prostate, and childhood cancers. He mentored 130 graduate students and postdoctoral fellows. In addition to his regular McGill teaching, he has taught short courses on cancer epidemiology and scientific publishing throughout the world. He is Editor-in-Chief of Preventive Medicine and Preventive Medicine Reports, as well as Senior Editor of eLife. He is Officer of the Order of Canada and Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. He received the Canadian Cancer Research Alliance’s Distinguished Service to Cancer Research Award; Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology and from the International Papillomavirus Society; the Women in U.S. Government’s Leadership Award; the Canadian Cancer Society’s Warwick Prize; the Geoffrey Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics; University of British Columbia’s Chew Wei Memorial Prize in Cancer Research; and the McLaughlin-Gallie Award from the Royal College of Physicians of Canada. He is Foreign Member of the Brazilian Academy of Sciences.

Eduardo Franco
Canada

Basic Sciences Track

Margaret Stanley
United Kingdom

Margaret Stanley is Emeritus Professor of Epithelial Biology in the University of Cambridge
and Honorary Fellow of Christs College, Cambridge. She has a lifetime award
for contribution to research on cervical cancer and cervical precancers from the American
Society for Colposcopy and Cytopathology (ASCCP) and a lifetime award for achievement
from the IPVS.

Margaret Stanley
United Kingdom

Clinical Research Track

Suzanne Garland
Australia

Professor Garland is an internationally recognized clinical microbiologist and sexual health physician, with particular expertise in infectious diseases as they pertain to reproductive health and the neonate. With her team, Prof Garland, has been a leader in the role of patient self-collected genital sampling in the detection by molecular techniques (polymerase chain reaction (PCR) of reproductive tract infections, particularly those sexually transmitted (STI), such as Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, herpes simplex virus and especially human papillomaviruses (HPV). She has published extensively on clinical epidemiology of STIs in Australia, with a focus on HPV. Her group has defined HPV in cervical dysplasia, cervical cancer, plus the healthy population within Australia. She was chief investigator of the study defining the prevalence of HPV genotypes in urban, rural, indigenous and non-indigenous Australian women (WHINURS project) pre-HPV vaccination program in Australia. She was chief investigator of two 4-year follow-up clinical trials of prophylactic HPV vaccines in young women, plus one in mid-age women. She leads an HPV vaccine effectiveness trial (VACCINE) in Australia which will be informative globally, particularly with the WHINURS data as baseline with which to compare outcomes post vaccination. She is a regular Advisor to the WHO, largely in the area of STI diagnosis, prophylactic HPV vaccines, as well as international standards for HPV DNA assays. She is invited to deliver keynote and plenary presentations at national and international meetings.

Professor Garland is the Director of the Centre for Women’s Infectious Diseases (WCID) at the Royal Women’s Hospital, the first clinical group to be centred in Bio 21 Institute, with affiliations to University of Melbourne Faculty of Medicine Dentistry and Health Sciences and the Department of Obstetrics and Gynaecology. WCID conducts clinical research, cutting edge molecular diagnostics as well as STI genosurveillance. Whilst key research areas of focus include cervical cancer, sexual health and mother-to-baby infections, it has an emphasis on providing evidence for changes that may translate into clinical practice, affecting patient health.

Suzanne Garland
Australia
Joel Palefsky
USA

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine. Dr. Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day. He is the founder and director of the world’s first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center. He is the chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium. He is the immediate past president of the International Papillomavirus Society and is the founder and immediate past president of the International Anal Neoplasia Society. He is a member of the ASCI and AAP. His research interests include the molecular pathogenesis and natural history of HPV-related disease, including in the setting of HIV infection, HPV prophylactic and therapeutic vaccines, secondary prevention of anal cancer, and treatment of HPV-related disease.

Joel Palefsky
USA

Public Health, Epidemiology & Implementation Science Track

Aimée Kreimer
USA

Dr. Kreimer is a senior investigator in the Infections & Immunoepidemiology Branch, within the Division of Cancer Epidemiology and Genetics, US National Cancer Institute. She is an Infetious Disease Epidemiologist by training and focuses her research on evalauting the protection afforded by HPV vaccine, undersntading HPV etiology at multiple anatomic sites, and investigating serologic biomarkers as risk predictors for HPV-driven cancers.

Aimée Kreimer
USA

Basic Sciences Workshop Track

Margaret Stanley
United Kingdom

Margaret Stanley is Emeritus Professor of Epithelial Biology in the University of Cambridge
and Honorary Fellow of Christs College, Cambridge. She has a lifetime award
for contribution to research on cervical cancer and cervical precancers from the American
Society for Colposcopy and Cytopathology (ASCCP) and a lifetime award for achievement
from the IPVS.

Margaret Stanley
United Kingdom

Clinical Research Workshop Track

Joel Palefsky
USA

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine. Dr. Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day. He is the founder and director of the world’s first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center. He is the chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium. He is the immediate past president of the International Papillomavirus Society and is the founder and immediate past president of the International Anal Neoplasia Society. He is a member of the ASCI and AAP. His research interests include the molecular pathogenesis and natural history of HPV-related disease, including in the setting of HIV infection, HPV prophylactic and therapeutic vaccines, secondary prevention of anal cancer, and treatment of HPV-related disease.

Joel Palefsky
USA

Public Health, Epidemiology & Implementation Science Workshop Track

Silvia de Sanjosé
USA

Dr. Silvia de Sanjosé is an MD, PhD with over 30 years of expertise in epidemiology of HPV and related cancers. She served as the President of the International Papillomavirus Society during 2015-2018 and has been Co-Chair of the Cape Town, Sydney and Barcelona (virtual) conferences of the IPVS. She has experience in large international studies involving HPV worldwide genotyping and has been involved in the development of HPV based screening guidelines for cervical cancer in Spain and in Catalonia. She has previously worked at the International Agency for Research on Cancer, the Catalan Institute of Oncology and PATH. Currently serving as Consultant for US NCI. Dr. de Sanjosé leads teams working to evaluate the use of artificial intelligence applied to cervical images. She is also involved in studies providing an insight on the association between HPV and HIV in cervical carcinogenesis applied to screening strategies. She is an affiliated professor at the Department of Epidemiology, University of Washington.

Silvia de Sanjosé
USA
Marc Steben
Canada

Dr Steben works a family doctor at the GMF la Cité du parc Lafontaine. He is president elect of the International society for STD research and will chair the 2025 conjoint meeting of the ISSTDR and International union against STI. He is a member of the Executive and responsible for the Education Committee of the International Papillomavirus society. He is chair of the Canadian HPV Prevention Network. He is the elected president of the Canadian branch of the International Union Against STIs. He is a member of the executive of the American Sexual Transmitted Association. He is associate editor of the Journal of Lower Genital Tract Disease and the Journal of Obstetrics and Gynecology of Canada. He is professor at the School of Public Health at Université de Montréal. He is co-chairman of HPV Global Action.

Marc Steben
Canada
Shelley Deeks
Canada

Dr. Shelley Deeks is the Deputy Chief Medical Officer of Health at the Department of Health and Wellness in Nova Scotia and an Associate Professor at the Dalla Lana School of Public Health, University of Toronto. She is the Chair of Canada’s National Advisory Committee on Immunization and a member of the World Health Organization Strategic Advisory Group of Experts Polio Working Group. Dr Deeks has over 25 years’ experience as a public health leader and over 150 publications and co-author on numerous NACI statements. She holds Fellowships in Public Health in both Canada and Australia and has worked at all levels of the public health system in Canada and at the national level in Australia.

Shelley Deeks
Canada
Yin Ling Woo
Malaysia

Professor Woo Yin Ling is a Professor of Obstetrics and Gynaecology at University of Malaya and a consultant gynaecological oncologist in University Malaya Medical Centre. She completed her specialist and subspecialty training in gynaecological oncology and postdoctoral research degree in the UK and was conferred her PhD by Cambridge University in 2008. Yin Ling received many awards for her professional excellence including the Royal College of Obstetrician and Gynaecologist Gold Medal and the Cancer Research UK Gordon Hamilton Fairley Fellowship. She returned to Malaysia in 2010 and have since been actively involved in of several research programs focusing on screening, prevention and management of gynaecological cancers in the Malaysian setting. Prof. Woo believes that any innovation in healthcare services must take into account the local resources with input from the stakeholders, particularly the women themselves. She is currently the country representative for the Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN), member of the Asia Pacific Economic Consortium (APEC) Cervical Cancer working group, member of the WHO screening and treatment working group (WHO), Committee member for policy at the International Papillomavirus Society (IPVS) and is a trustee to ROSE Foundation.

Yin Ling Woo
Malaysia
Mona Saraiya
USA

Mona Saraiya, MD, MPH, is a Medical Officer and Team Lead in CDC’s Division of Cancer Prevention and Control’s (DCPC’s) Epidemiology and Applied Research Branch. Prior to her current position, Dr. Saraiya was Associate Director of DCPC’s Office of International Cancer Control. She has also worked on domestic issues related to skin cancer epidemiology and cervical cancer prevention and control. Her cervical cancer and human papillomavirus (HPV) research portfolio includes an initiative to characterize the HPV-associated cancer burden in the United States, and adherence to cervical cancer screening guidelines, especially with newer technologies such as HPV testing.
She graduated from Rush Medical College, completed a Masters of Public Health at Emory School of Public Health, completed a residency in Preventive Medicine/Public Health, and is board certified by the American College of Preventive Medicine.

Mona Saraiya
USA
Mark Schiffman
USA

Dr. Schiffman has studied human papillomavirus (HPV) and cervical cancer for more than 35 years. He has conducted and collaborated on many large molecular epidemiologic observational studies and a few major trials Through a natural progression of studies, he has pursued three main scientific themes: 1) HPV Natural History and Cervical Carcinogenesis; 2) Translational Studies of HPV Testing, Cytology, Colposcopy, and Vaccines; and 3) Risk Prediction and Cervical Cancer Prevention.
With regard to natural history, he has investigated HPV at the level of individual infections, women’s experience with HPV during their lifetimes, and populations. His work has helped promulgate a multi-stage causal model of HPV and cervical carcinogenesis based on a few distinct steps: acute infection with carcinogenic HPV type(s), detectable viral persistence (rather than clearance) linked to development of cervical precancer (CIN3/AIS and invasion). The natural history studies gave rise to translational research on HPV tests, serology, cytology, colposcopy, histology, and vaccines. He has helped to show that HPV testing is useful along the entire course of cervical cancer prevention, and must be integrated now with HPV vaccination. With Dr. Nicolas Wentzensen, he is the Principal Investigator of the Cancer Cures “Moonshot” Initiative called “Accelerated Control of Cervical Cancer.” His emphasis is on practical screening strategies for resource-limited settings. The effort is combining extended genotyping of self-collected vaginal specimens with visual triage, assisted by a deep-learning trained algorithm, named ``automated visual evaluation``.

Mark Schiffman
USA
Rolando Herrero
Costa Rica

Rolando Herrero is a Costa Rican oncologist and epidemiologist with a long trajectory of research on HPV-associated cancers, including natural history, screening and vaccination studies. His recent focus has been on evaluating, in collaboration with the US NCI, alternative vaccination schedules to increase access and impact of HPV vaccines. He is also conducting a large evaluation of triage techniques among HPV positive women in Latin America: the ESTAMPA study. Formerly Head of the Early Detection and Prevention Section at IARC, Dr Herrero is currently the Scientific Director of ACIB (Agencia Costarricense de Investigaciones Biomedicas) and during the last year has also initiated a large prospective study to evaluate the immune response to the Sars-CoV-2 virus in Costa Rica.

Rolando Herrero
Costa Rica
Aisha Lofters
Canada

Aisha is a scientist at the Women's College Research Institute (WCRI), adjunct scientist at IC/ES, and an Associate Professor in the Department of Family and Community Medicine at the University of Toronto. She currently holds a New Investigator Award from the Canadian Institutes of Health Research, and holds the Chair in Implementation Science at the Peter Gilgan Centre for Women’s Cancers at Women’s College Hospital in partnership with the Canadian Cancer Society.

Aisha is also the Provincial Primary Care Lead, Cancer Screening at Cancer Care Ontario (Ontario Health). Her research program focusses on improving quality of care in cancer screening and prevention, particularly for populations that experience marginalization.

Aisha Lofters
Canada
Paul Bloem
Switzerland

Mr Paul Bloem is a public health practitioner with an MBA in Health Systems Management. Worked in public health research (TNO-NIPG) in his native Netherlands, for an NGO in Costa Rica and for UNICEF’s Central American Office in Guatemala, before joining the World Health Organization in 1996. His career focused on improving the health of adolescents, through health promotion and the quality of care for adolescents. In 2012 he joined the IVB Department to dedicate himself to HPV vaccination and integration with adolescent health. He currently is the HPV vaccine lead in WHO in Geneva supporting norms and standards setting on HPV vaccination through SAGE and developing technical reference materials. He provides technical support for the introduction of the HPV vaccine in low and middle income countries and has carried out program evaluations in all regions. Member of GAVI HPV Subteam advising GAVI on the implementation of its HPV programme. Within the Secretariat for the Global Strategy on Cervical Cancer Elimination, he supports the primary prevention through HPV vaccination.

Paul Bloem
Switzerland
Mario Poljak
Slovenia

Mario Poljak, MD, PhD, specialist in clinical microbiology, is Professor of Microbiology and Immunology and Head of Laboratory for Molecular Microbiology at Faculty of Medicine, University of Ljubljana, Slovenia.
He was ESCMID President from 2016-2018.
He is author of 430+ original research or review articles published in PubMed-cited journals. His papers have been cited more than 14,000 times (Hirsch index=56).
As invited speaker he gave more than 370 lectures at international and national scientific and professional meetings.
He has been active in the HPV field for past 30 years and has been a member of IPVS since 2002.

Mario Poljak
Slovenia
Julia Brotherton
Australia

Assoc Prof Julia Brotherton is a public health physician, epidemiologist and Medical Director of Population Health at VCS Foundation. She is an Honorary Principal Fellow at the Melbourne School of Population and Global Health and Professorial Fellow at the National Centre for Immunisation Research and Surveillance. For over 15 years, Julia has been involved in research and policy development informing the implementation and evaluation of HPV vaccination and cervical screening programs. She is a member of the WHO Director General’s Expert Advisory Group on Cervical Cancer Elimination, the International Agency for Research on Cancer (IARC) Working Group for Handbook 18 on Cervical Screening, and of the global HPV Vaccine Council and is a CI of the NHMRC Centre of Research Excellence in Cervical Cancer Control.

Julia Brotherton
Australia
Karen Canfell
Australia

Professor Karen Canfell is the inaugural Director of the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW. She is an epidemiologist, modeller, and a translationally-focused population health researcher. She has led evaluations of new cancer screening approaches for government agencies in several countries. She currently leads Compass, which is the first major international experience of cervical screening in an HPV-vaccinated population. Her team’s work underpins the 2017 transition of the National Cervical Screening Program in Australia from Pap smears to 5-yearly HPV-based screening. She currently has active collaborative modelling grants from the US NIH and WHO to model cervical cancer prevention in the USA and globally. Her work as one of the co-leads of the WHO Cervical Cancer Elimination Modelling Consortium was presented and discussed at the Executive Board of the World Health Assembly in 2020 and supported the formal resolution by WHO to support the cervical cancer elimination initiative, launched in late 2020. Most recently she led modelling to support new WHO cervical screening guidelines, launched in July 2021.

Karen Canfell
Australia
Rose Anorlu
Nigeria

Rose Anorlu MBChB, MPH, FMCOG, FWACS, FRCOG is a Professor of Obstetrics and Gynaecology in University of Lagos, Nigeria. She has been working in Nigeria throughout her career in obstetrics and gynaecology. Her interest is in cervical cancer prevention and treatment.
She has published widely in peer reviewed scientific journals and has supervised to date 24 dissertations (10 of which are on cervical cancer and other HPV related diseases of the of the female genital tract) for Fellowship Examinations of the National Postgraduate Medical College of Nigeria and West Africa College of Surgeons. She was a Co- Investigator in Study EPI-HPV-109117 by Glaxo Smith Klein (GSK) 2008-2010-a multinational study on HPV types study in women with invasive cervical cancer in sub-Saharan Africa. She is currently the Project Lead in the U54 Project 2 -Epigenomic Biomarkers of HIV Associated Cancers in Nigeria U54CA221206 (NIH). (2018-2022)
Besides her academic and clinical work, she also does a lot of community work. She has been involved in training of trainers in cervical cancer prevention in Lagos and other parts of Nigeria since 2008. She helped with support from Women’s Health, Elizabeth Garret Anderson Hospital, UCLH in setting up a Cervical Cancer Prevention Clinic in St Kizito Primary Health Centre in Lekki, Lagos, in 2006. She organized with members of Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, the 1st HPV Awareness Day in Lagos in 2018.
She was Council Member of the International Gynaecological Cancer Society representing Africa, Europe and the Middle East (2010-2014). She was a member the Committee that drafted the National Cervical Cancer Cancer Control Plan for Nigeria (2018– 2022) and is a member of the Implementation Committee, National Strategy for Cervical Cancer Control 2019-to date

Rose Anorlu is currently the President-Elect of Africa Organization for Research and Training in Cancer (AORTIC).

Rose Anorlu
Nigeria

Early Career Researcher Program Committee:

Ann Burchell
Canada

Dr. Ann Burchell is Research Director at the Department of Family and Community Medicine and Scientist at the MAP Centre for Urban Health Solutions at St. Michael’s Hospital, Toronto. She is a Canada Research Chair in Sexually Transmitted Infection Prevention. She holds degrees in epidemiology from the University of Toronto (MSc) and McGill University (PhD) and has academic appointments as Associate Professor, Department of Family and Community Medicine, Faculty of Medicine, and Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto; Adjunct Professor, Division of Cancer Epidemiology, McGill University; and Adjunct Scientist, Institute for Clinical Evaluative Medicine, Toronto.

Dr. Burchell’s research program focuses on the epidemiology of human immunodeficiency virus (HIV) infection, human papillomavirus (HPV), syphilis, and other sexually transmitted infections (STIs). Its goal is to generate evidence for effective and practical strategies to prevent STIs and STI-related cancers in high-risk populations, including people living with or at risk for HIV.

She has extensive methodological experience in the design and implementation of: observational longitudinal studies with primary and secondary data; sexual behaviour and health-access questionnaires; natural history studies using laboratory markers of infection; and pragmatic randomized trials for HPV prevention and improved screening for syphilis, cervical and anal cancer. She currently holds a Foundation Grant from the Canadian Institutes of Health Research.

Ann Burchell
Canada
Eduardo Franco
Canada

He is trained in public health microbiology at University of North Carolina and at the Centers for Disease Control, and as a cancer epidemiologist at the National Institutes of Health, International Agency for Research on Cancer, and Louisiana State University. Since 1985, his research has focused on epidemiology and prevention of gynecologic, anogenital, oral, prostate, and childhood cancers. He mentored 130 graduate students and postdoctoral fellows. In addition to his regular McGill teaching, he has taught short courses on cancer epidemiology and scientific publishing throughout the world. He is Editor-in-Chief of Preventive Medicine and Preventive Medicine Reports, as well as Senior Editor of eLife. He is Officer of the Order of Canada and Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. He received the Canadian Cancer Research Alliance’s Distinguished Service to Cancer Research Award; Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology and from the International Papillomavirus Society; the Women in U.S. Government’s Leadership Award; the Canadian Cancer Society’s Warwick Prize; the Geoffrey Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics; University of British Columbia’s Chew Wei Memorial Prize in Cancer Research; and the McLaughlin-Gallie Award from the Royal College of Physicians of Canada. He is Foreign Member of the Brazilian Academy of Sciences.

Eduardo Franco
Canada
Jennifer Gillis
Canada

Dr. Gillis is a Post-doctoral Fellow at the University of British Columbia and the BC Children’s and Women’s Hospitals in Canada. Dr. Gillis received her PhD in Epidemiology from the University of Toronto in Canada. Her PhD dissertation focused on the acceptability and suitability of anal cancer screening by anal Pap cytology and HPV DNA type testing among men living with HIV. In her post-doctoral work with Drs. Gina Ogilvie and Manish Sadarangani, Dr. Gillis is examining the long-term effectiveness and immunogenicity of reduced dosing schedules of the HPV vaccine. In all her work, Dr. Gillis places emphasis on meaningful engagement of community and research partners. Her work has been recognized by numerous national awards in Canada and funded by Canadian national partners such as the Canadian Institutes of Health Research and the Ontario HIV Treatment Network.

Jennifer Gillis
Canada
Anna Yeung
Canada

Anna Yeung
Canada
Eric Chow
Australia

Associate Professor Eric Chow is an epidemiologist and biostatistician based at the Melbourne Sexual Health Centre (MSHC) at The Alfred Hospital. He heads the Health Data Management and Biostatistics Unit at MSHC and is an Associate Professor at Central Clinical School, Monash University. He is also an Honorary Principal Fellow at the Melbourne School of Population & Global Health, The University of Melbourne.

A/Prof Chow’s research program aims to improve treatment, prevention and control of sexually transmitted infections (STI), with a particular focus on gonorrhoea and human papillomavirus (HPV). His work focuses on the evaluation of the national school-based HPV vaccination program. He has led several studies looking at the impact of the implementation of the gender-neutral HPV vaccination program (e.g. epidemiology of genital warts and HPV prevalence) and the implementation of time-limited catch-up programme for men who have sex with men (e.g. vaccination uptake). His work on HPV has helped to inform HPV guidelines abroad.

Eric Chow
Australia
Troy Grennan
Canada

Dr. Troy Grennan is an infectious diseases physician and researcher in Vancouver, Canada. He is currently the Physician Lead for the Provincial HIV/STI Program at the BC Centre for Disease Control, as well as a Clinical Associate Professor in the Division of Infectious Diseases at the University of British Columbia. Following specialty training in infectious diseases and medical microbiology, he completed a CIHR Canadian HIV Trials Network postdoctoral fellowship examining human papillomavirus (HPV)-associated anal cancer screening in HIV-positive men who have sex with men (MSM). He is currently Co-Principal Investigator on the CIHR Team Grant “HPV Screening and Vaccine Evaluation in HIV-Positive MSM” and the recently funded, “Predicting and Evaluating Anal Cancer in HIV (PEACH) using novel biomarkers”, as well as a number of other projects examining anal cancer screening and HPV vaccination in MSM. His other research and clinical work focuses on HIV and STI prevention with a focus on MSM, and he is Principal Investigator on the DISCO (Doxycycline as an Intervention for STI ChemOprophylaxis) study, a multicentre RCT examining the use of doxycycline for bacterial STI prevention.

Troy Grennan
Canada
Michelle Ozbun
USA

Professor Ozbun is the Maralyn S. Budke Endowed Professor in Viral Oncology at the UNM Comprehensive Cancer Center of The University of New Mexico School of Medicine. She holds academic appointments in the Departments of Molecular Genetics & Microbiology (primary) and Obstetrics & Gynecology at The UNM School of Medicine. She is also the Co-leader of the Head and Neck Cancer Clinical Working Group at The UNM Comprehensive Cancer Center. She is the PI of the American Cancer Society’s Institutional Research Grant to UNM and the Program Director of the NIH NIAID NRSA-Funded “Infectious Disease and Inflammation Program” (IDIP) T32 Training Program.

Dr. Ozbun received a bachelor of science degree in Microbiology, with a minor in Chemistry, from Colorado State University in 1987 and a Ph.D. in Molecular Virology (with Janet S. Butel, Ph.D.) from Baylor College of Medicine, Houston, Texas, in 1994. She completed US-NIH-funded postdoctoral training with Dr. Craig Meyers at the Penn State University College of Medicine in Hershey, Pennsylvania from 1994-1998. Dr. Ozbun joined the faculty of the University of New Mexico School of Medicine in 1998.

Research in Dr. Ozbun’s lab spans from the basic science molecular virology of human papillomavirus infections and cancer progression to efforts aimed at HPV lesion treatments and improving clinical outcomes. In 16 years of continuous US-NIH funding as a PI, Dr. Ozbun and her research group have striven to improve our understanding of HPV infections and carcinogenesis by challenging the status quo and dogma in the HPV field using all available methods for virion production and replication, and insisting upon biologically relevant cell, tissue, and animal models for the study of infection and pathogenesis. In 2018 she was elected as the treasurer of the International Papillomavirus Society.

Michelle Ozbun
USA
Cary Moody
USA

Cary Moody
USA
Sam Campos
USA

Sam Campos
USA
Aisha Lofters
Canada

Aisha is a scientist at the Women's College Research Institute (WCRI), adjunct scientist at IC/ES, and an Associate Professor in the Department of Family and Community Medicine at the University of Toronto. She currently holds a New Investigator Award from the Canadian Institutes of Health Research, and holds the Chair in Implementation Science at the Peter Gilgan Centre for Women’s Cancers at Women’s College Hospital in partnership with the Canadian Cancer Society.

Aisha is also the Provincial Primary Care Lead, Cancer Screening at Cancer Care Ontario (Ontario Health). Her research program focusses on improving quality of care in cancer screening and prevention, particularly for populations that experience marginalization.

Aisha Lofters
Canada
Barbara Moscicki
USA

Barbara Moscicki
USA
Greg Zimet
USA

Dr. Zimet is Professor of Pediatrics and Psychiatry in the Division of Adolescent Medicine, Department of Pediatrics at Indiana University School of Medicine in the U.S. In addition, he is the founder and Co-Director of the Indiana University-Purdue University Indianapolis (IUPUI) Center for HPV Research. Dr. Zimet started investigating attitudes about vaccines for adolescents in the mid-1990s. Much of his research has involved the study of vaccine acceptance and refusal, with a primary focus over the past 20 years on HPV vaccine. Dr. Zimet’s research has encompassed behavioral, social, and policy-based determinants of HPV vaccination. His studies, which have included collaborations across the United States and globally, have focused on adolescents, adults, parents, and health care providers and include evaluations of vaccine communication intervention strategies.

Greg Zimet
USA